{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:28:28Z","timestamp":1787023708886,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100010101","name":"Taichung Veterans General Hospital","doi-asserted-by":"publisher","award":["TCVGH-YM1090104"],"award-info":[{"award-number":["TCVGH-YM1090104"]}],"id":[{"id":"10.13039\/501100010101","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010101","name":"Taichung Veterans General Hospital","doi-asserted-by":"publisher","award":["TCVGH-VHCY1088605"],"award-info":[{"award-number":["TCVGH-VHCY1088605"]}],"id":[{"id":"10.13039\/501100010101","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010101","name":"Taichung Veterans General Hospital","doi-asserted-by":"publisher","award":["TCVGH-1087325D"],"award-info":[{"award-number":["TCVGH-1087325D"]}],"id":[{"id":"10.13039\/501100010101","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s10067-026-08185-w","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T02:45:18Z","timestamp":1782096318000},"page":"4869-4880","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Healthcare utilization and costs in patients with rheumatoid arthritis using biologics or tofacitinib: a nationwide, population-based study"],"prefix":"10.1007","volume":"45","author":[{"given":"Yen-Ju","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Li","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsian-Min","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Ming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7304-4587","authenticated-orcid":false,"given":"Hsin-Hua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"8185_CR1","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Aletaha D, McInnes IB (2016) Rheumatoid arthritis. Lancet 388:2023\u20132038","journal-title":"Lancet"},{"key":"8185_CR2","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1007\/s00296-017-3726-1","volume":"37","author":"TM Hunter","year":"2017","unstructured":"Hunter TM, Boytsov NN, Zhang X, Schroeder K, Michaud K, Araujo AB (2017) Prevalence of rheumatoid arthritis in the United States adult population in healthcare claims databases, 2004-2014. Rheumatol Int 37:1551\u20131557","journal-title":"Rheumatol Int"},{"key":"8185_CR3","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s00296-012-2411-7","volume":"33","author":"CF Kuo","year":"2013","unstructured":"Kuo CF, Luo SF, See LC, Chou IJ, Chang HC, Yu KH (2013) Rheumatoid arthritis prevalence, incidence, and mortality rates: a nationwide population study in Taiwan. Rheumatol Int 33:355\u2013360","journal-title":"Rheumatol Int"},{"key":"8185_CR4","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.jbspin.2016.10.010","volume":"84","author":"A Mazouy\u00e8s","year":"2017","unstructured":"Mazouy\u00e8s A, Clay M, Bernard AC, Gaudin P, Baillet A (2017) Efficacy of triple association methotrexate, sulfasalazine and hydroxychloroquine in early treatment of rheumatoid arthritis with insufficient response to methotrexate: meta-analysis of randomized controlled trials. Joint Bone Spine 84:563\u2013570","journal-title":"Joint Bone Spine"},{"key":"8185_CR5","first-page":"S237","volume":"13","author":"V Strand","year":"2007","unstructured":"Strand V, Singh JA (2007) Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials. Am J Manag Care 13:S237\u2013S251","journal-title":"Am J Manag Care"},{"key":"8185_CR6","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Landewe RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A et al (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 79:685\u2013699","journal-title":"Ann Rheum Dis"},{"key":"8185_CR7","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/acr.24596","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, Carandang K et al (2021) 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 73:924\u2013939","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"8185_CR8","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1002\/acr.21755","volume":"64","author":"AA Kawatkar","year":"2012","unstructured":"Kawatkar AA, Jacobsen SJ, Levy GD, Medhekar SS, Venkatasubramaniam KV, Herrinton LJ (2012) Direct medical expenditure associated with rheumatoid arthritis in a nationally representative sample from the Medical Expenditure Panel Survey. Arthritis Care Res (Hoboken) 64:1649\u20131656","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"8185_CR9","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1093\/rheumatology\/ket290","volume":"53","author":"A Kalkan","year":"2014","unstructured":"Kalkan A, Hallert E, Bernfort L, Husberg M, Carlsson P (2014) Costs of rheumatoid arthritis during the period 1990-2010: a register-based cost-of-illness study in Sweden. Rheumatology (Oxford) 53:153\u2013160","journal-title":"Rheumatology (Oxford)"},{"key":"8185_CR10","doi-asserted-by":"publisher","first-page":"323","DOI":"10.2165\/11589470-000000000-00000","volume":"30","author":"HG Birnbaum","year":"2012","unstructured":"Birnbaum HG, Pike C, Banerjee R, Waldman T, Cifaldi M (2012) Changes in utilization and costs for patients with rheumatoid arthritis, 1997 to 2006. Pharmacoeconomics 30:323\u2013336","journal-title":"Pharmacoeconomics"},{"key":"8185_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0200758","volume":"13","author":"KC Chen","year":"2018","unstructured":"Chen KC, Wu CH, Tang CH, Huang KC (2018) Healthcare resource utilization and costs among patients with rheumatoid arthritis on biologic therapies in Taiwan: a 1-year mirror-image study using a national claims database. PLoS ONE 13:e0200758","journal-title":"PLoS ONE"},{"key":"8185_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01214","volume":"10","author":"DY Chen","year":"2019","unstructured":"Chen DY, Yu F, Tuan LW, Tang CH (2019) Comparison of healthcare utilization and costs between RA patients receiving biological and conventional synthetic DMARDs: a nationwide population-based cohort study in Taiwan. Front Pharmacol 10:1214","journal-title":"Front Pharmacol"},{"key":"8185_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0251334","volume":"16","author":"M Tatangelo","year":"2021","unstructured":"Tatangelo M, Tomlinson G, Paterson JM, Keystone E, Bansback N, Bombardier C (2021) Health care costs of rheumatoid arthritis: a longitudinal population study. PLoS ONE 16:e0251334","journal-title":"PLoS ONE"},{"key":"8185_CR14","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X211024830","volume":"13","author":"H Kim","year":"2021","unstructured":"Kim H, Cho SK, Choi S, Im SG, Jung SY, Jang EJ et al (2021) Comparison of healthcare resource utilization and medical costs between patients with seropositive and seronegative rheumatoid arthritis. Ther Adv Musculoskelet Dis 13:1759720X211024830","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"8185_CR15","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315\u201324","journal-title":"Arthritis Rheum"},{"key":"8185_CR16","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd et al (2010) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European league against rheumatism collaborative initiative. Arthritis Rheum 62:2569\u20132581","journal-title":"Arthritis Rheum"},{"key":"8185_CR17","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373\u2013383","journal-title":"J Chronic Dis"},{"key":"8185_CR18","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1007\/s12325-017-0596-6","volume":"34","author":"NA Accortt","year":"2017","unstructured":"Accortt NA, Schenfeld J, Chang E, Papoyan E, Broder MS (2017) Changes in healthcare utilization after etanercept initiation in patients with rheumatoid arthritis: a retrospective claims analysis. Adv Ther 34:2093\u20132103","journal-title":"Adv Ther"},{"key":"8185_CR19","first-page":"7","volume":"26","author":"YH Chen","year":"2012","unstructured":"Chen YH, Su WJ, Shen GH, Chen DY, Lu LY, Huang DF et al (2012) Screening and management of tuberculosis infection in patients scheduled for tumor necrosis factor -alpha inhibitors: consensus recommendations from the Taiwan Rheumatology Association. Formosan J Rheumatol 26:7","journal-title":"Formosan J Rheumatol"},{"key":"8185_CR20","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1080\/14397595.2017.1369926","volume":"28","author":"Y Shimizu","year":"2018","unstructured":"Shimizu Y, Tanaka E, Inoue E, Shidara K, Sugimoto N, Seto Y et al (2018) Reduction of methotrexate and glucocorticoids use after the introduction of biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis in daily practice based on the IORRA cohort. Mod Rheumatol 28:461\u2013467","journal-title":"Mod Rheumatol"},{"key":"8185_CR21","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s40744-018-0095-5","volume":"5","author":"M Okazaki","year":"2018","unstructured":"Okazaki M, Kobayashi H, Ishii Y, Kanbori M, Yajima T (2018) Real-world treatment patterns for golimumab and concomitant medications in Japanese rheumatoid arthritis patients. Rheumatol Ther 5:185\u2013201","journal-title":"Rheumatol Ther"},{"key":"8185_CR22","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s40744-020-00228-1","volume":"7","author":"F Yamairi","year":"2020","unstructured":"Yamairi F, Yano T, Goto T, Iwasaki T (2020) Dose adjustment of methotrexate administered concomitantly with golimumab for rheumatoid arthritis in Japanese real-world clinical settings. Rheumatol Ther 7:811\u2013824","journal-title":"Rheumatol Ther"},{"key":"8185_CR23","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s40744-019-0150-x","volume":"6","author":"B Haraoui","year":"2019","unstructured":"Haraoui B, Casado G, Czirj\u00e1k L, Taylor A, Dong L, Button P et al (2019) Tocilizumab patterns of use, effectiveness, and safety in patients with rheumatoid arthritis: final results from a set of multi-national non-interventional studies. Rheumatol Ther 6:231\u2013243","journal-title":"Rheumatol Ther"},{"key":"8185_CR24","doi-asserted-by":"crossref","unstructured":"Gabay C, Emery P, van Vollenhoven R, Dikranian A, Alten R, Pavelka K, ADACTA Study Investigators et al (2013) Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 38:1541\u201350","DOI":"10.1016\/S0140-6736(13)60250-0"},{"key":"8185_CR25","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s40744-020-00200-z","volume":"7","author":"DA Pappas","year":"2020","unstructured":"Pappas DA, Blachley T, Zlotnick S, Best J, Emeanuru K, Kremer JM (2020) Methotrexate discontinuation and dose decreases after therapy with tocilizumab: results from the Corrona rheumatoid arthritis registry. Rheumatol Ther 7:357\u2013369","journal-title":"Rheumatol Ther"},{"issue":"1","key":"8185_CR26","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13075-020-02408-4","volume":"23","author":"DH Solomon","year":"2021","unstructured":"Solomon DH, Xu C, Collins J, Kim SC, Losina E, Yau V et al (2021) The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy. Arthritis Res Ther 23:26","journal-title":"Arthritis Res Ther"},{"key":"8185_CR27","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.3899\/jrheum.201626","volume":"48","author":"FD Johansson","year":"2021","unstructured":"Johansson FD, Collins JE, Yau V, Guan H, Kim SC, Losina E et al (2021) Predicting response to tocilizumab monotherapy in rheumatoid arthritis: a real-world data analysis using machine learning. J Rheumatol 48:1364\u20131370","journal-title":"J Rheumatol"},{"key":"8185_CR28","first-page":"1003","volume":"37","author":"A Giusti","year":"2019","unstructured":"Giusti A, Epis OM, Migliore A, Ricioppo A, Sainaghi PP, Di Matteo L et al (2019) The effect of gender on methotrexate prescription attitudes in Italian rheumatoid arthritis patients: the MARI study. Clin Exp Rheumatol 37:1003\u20131009","journal-title":"Clin Exp Rheumatol"},{"key":"8185_CR29","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1007\/s10165-004-0340-3","volume":"14","author":"H Kameda","year":"2004","unstructured":"Kameda H, Amano K, Sekiguchi N, Takei H, Ogawa H, Nagasawa H et al (2004) Factors predicting the response to low-dose methotrexate therapy in patients with rheumatoid arthritis: a better response in male patients. Mod Rheumatol 14:442\u20136","journal-title":"Mod Rheumatol"},{"key":"8185_CR30","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/j.1445-5994.2009.01800.x","volume":"39","author":"N Varatharajan","year":"2009","unstructured":"Varatharajan N, Lim IG, Anandacoomarasamy A, Russo R, Byth K, Spencer DG et al (2009) Methotrexate: long-term safety and efficacy in an Australian consultant rheumatology practice. Intern Med J 39:228\u201336","journal-title":"Intern Med J"},{"key":"8185_CR31","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.3899\/jrheum.090838","volume":"37","author":"J Drouin","year":"2010","unstructured":"Drouin J, Haraoui B, 3e Initiative Group (2010) Predictors of clinical response and radiographic progression in patients with rheumatoid arthritis treated with methotrexate monotherapy. J Rheumatol 37:1405\u201310","journal-title":"J Rheumatol"},{"key":"8185_CR32","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1001\/jama.1949.02900430001001","volume":"140","author":"O Steinbrocker","year":"1949","unstructured":"Steinbrocker O, Traeger CH, Batterman RC (1949) Therapeutic criteria in rheumatoid arthritis. J Am Med Assoc 140:659\u2013662","journal-title":"J Am Med Assoc"},{"key":"8185_CR33","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3899\/jrheum.120441","volume":"40","author":"LR Harrold","year":"2013","unstructured":"Harrold LR, Briesacher BA, Peterson D, Beard A, Madden J, Zhang F et al (2013) Cost-related medication nonadherence in older patients with rheumatoid arthritis. J Rheumatol 40:137\u201343","journal-title":"J Rheumatol"},{"key":"8185_CR34","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1136\/annrheumdis-2019-216243","volume":"79","author":"PH Hsieh","year":"2020","unstructured":"Hsieh PH, Wu O, Geue C, McIntosh E, McInnes IB, Siebert S (2020) Economic burden of rheumatoid arthritis: a systematic review of literature in biologic era. Ann Rheum Dis 79:771\u2013777","journal-title":"Ann Rheum Dis"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08185-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-026-08185-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08185-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:16:22Z","timestamp":1787022982000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-026-08185-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["8185"],"URL":"https:\/\/doi.org\/10.1007\/s10067-026-08185-w","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"assertion":[{"value":"18 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Institutional Review Board of Taichung Veterans General Hospital, Taiwan, approved this study (CE19038A). Because de-identified data were released for research purposes only by Taiwan\u2019s NHIRD, the requirement of informed consent for each participant was waived by the Institutional Review Board of Taichung Veterans General Hospital due to retrospective nature of study. Research was performed in accordance with the Declaration of Helsinki, and all methods were carried out in accordance with relevant guidelines and regulations.","order":1,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Compliance with ethical standard"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Compliance with ethical standard"}},{"value":"None.","order":3,"name":"Ethics","label":"Disclosures","group":{"name":"EthicsHeading","label":"Compliance with ethical standard"}}]}}